Zimmer Biomet Holdings
ZBH
$85.14
+1.72%
Zimmer Biomet Holdings, Inc. is a global leader in the medical devices industry, specifically designing, manufacturing, and marketing orthopedic reconstructive implants, surgical equipment, and related supplies. The company holds a dominant market share in the reconstructive market across the United States, Europe, and Japan, with its core business heavily weighted towards large joints like hips and knees. The current investor narrative revolves around the company's post-spin-off focus and its ability to deliver consistent growth in its core orthopedic segments, amidst a backdrop of competitive pressures and macroeconomic factors influencing elective procedure volumes.…
ZBH
Zimmer Biomet Holdings
$85.14
Investment Opinion: Should I buy ZBH Today?
Rating: Hold. The core thesis is that ZBH presents a compelling long-term valuation case clouded by severe near-term operational and sentiment headwinds, requiring a wait-and-see approach before committing capital.
Supporting this Hold rating are four key data points. First, the forward PE of 9.31x is deeply discounted, implying a significant earnings rebound. Second, the implied analyst target of ~$103.44 offers 23.6% upside. Third, the company's financial foundation is solid, with $1.85B in TTM FCF and a manageable debt-to-equity of 0.59. Fourth, the stock is technically oversold, trading just 5.8% above its 52-week low. However, these positives are counterbalanced by a trailing PE premium of 25.25x, a 40% sequential drop in net income, and sharply negative price momentum.
The thesis would upgrade to a Buy if the company demonstrates QoQ margin stabilization in the next earnings report, confirming the forward EPS estimates, and the stock holds above the $79.12 support level. It would downgrade to a Sell if Q4 margin compression continues, leading to downward revisions of the $11.115 EPS estimate, or if the stock decisively breaks below the $79 low. Currently, the stock is fairly valued for the elevated risk it carries; it is not overvalued based on forward estimates but is rightly discounted for its operational uncertainty.
Sign up to view all
ZBH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The valuation is undeniably cheap if the earnings rebound materializes, creating a asymmetric risk/reward setup skewed to the upside over the long term. However, the near-term evidence—plummeting margins, negative momentum, and cautious analysts—argues strongly for patience. The stance would upgrade to bullish on confirmation of margin stabilization in the next 1-2 quarters, as this would validate the forward earnings power. It would turn bearish if the next quarterly report shows continued deterioration, proving the low forward multiple was warranted for a deteriorating business. The high free cash flow and solid balance sheet limit the absolute downside, making a catastrophic decline unlikely, but the path to realizing the upside is currently obstructed.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Zimmer Biomet Holdings's 12-month outlook, with a consensus price target around $110.68 and implied upside of +30.0% versus the current price.
Average Target
$110.68
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$68 - $111
Analyst target range
The stock is covered by 9 analysts, indicating solid institutional interest. The consensus recommendation leans neutral to cautious, with recent actions including a downgrade from BTIG to 'Neutral' from 'Buy' in March 2026, alongside maintains of 'Underweight', 'Equal Weight', and 'Sell' ratings from other firms. The average target price implied by EPS and revenue estimates suggests a target around $103.44 (based on forward PE of 9.31x and estimated EPS of $11.115), which would imply a potential upside of approximately 23.6% from the current price of $83.7, though a formal consensus target price is not provided in the data. The target range is wide, with estimated revenue spanning from $9.78 billion to $10.03 billion and EPS from $10.91 to $11.27, reflecting uncertainty around the pace of recovery and competitive dynamics. The recent downgrade by BTIG signals a shift in sentiment, suggesting some analysts are growing less confident in the near-term turnaround story, which contributes to the stock's weak technical performance.
Bulls vs Bears: ZBH Investment Factors
The investment debate for ZBH centers on a stark clash between compelling value and deteriorating momentum. The bull case, supported by a deeply discounted forward PE of 9.31x, strong cash flow, and a 23.6% implied upside to analyst targets, appears fundamentally stronger on a long-term valuation basis. However, the bear case currently holds the momentum, evidenced by severe margin compression, accelerating price declines, and a cautious shift in analyst sentiment. The single most important tension is whether the company can stabilize and recover its profitability margins as anticipated by forward estimates. If Q4's margin collapse proves transient and the earnings rebound materializes, the stock is significantly undervalued. If the margin weakness persists, the low forward multiple will expand, and the stock's premium trailing valuation will unravel, leading to further downside.
Bullish
- Deeply Undervalued Forward PE: The stock trades at a forward PE of 9.31x based on estimated EPS of $11.115, representing a significant discount to its trailing PE of 25.25x and the broader sector. This low multiple prices in a substantial earnings recovery, offering a wide margin of safety if the company meets or exceeds expectations.
- Strong Cash Flow Generation: Zimmer Biomet generated $1.85 billion in trailing twelve-month free cash flow, providing ample internal funding for dividends, share buybacks, and strategic investments. This robust cash generation, coupled with a solid current ratio of 1.98, significantly de-risks the balance sheet and supports shareholder returns.
- Analyst Target Implies 23.6% Upside: The average analyst target price, implied by a forward PE of 9.31x and estimated EPS of $11.115, is approximately $103.44. This suggests a potential upside of 23.6% from the current price of $83.7, indicating fundamental value not reflected in the current technical weakness.
- Resilient Core Revenue Growth: Q4 2025 revenue grew 10.9% year-over-year to $2.24 billion, demonstrating underlying demand strength in its core knee ($911M) and hip ($555.4M) segments. This growth occurred despite a sequential dip, highlighting the company's market leadership in large joint reconstruction.
Bearish
- Severe Margin Compression & Earnings Volatility: Q4 2025 net margin collapsed to 6.2% from 11.5% in Q3, while gross margin fell to 64.68% from 72.05%. This dramatic quarterly volatility in profitability, with net income dropping 40% sequentially to $139.5M, raises serious concerns about earnings quality and cost management.
- Accelerating Negative Momentum & Downtrend: The stock is down 13.47% over the past year and 11.15% over the past month, severely underperforming the S&P 500 by 16.75 percentage points in the last month. This accelerating downtrend, trading near 52-week lows, indicates persistent selling pressure and a lack of positive catalysts.
- Analyst Sentiment Turning Cautious: Recent analyst actions include a downgrade from BTIG to 'Neutral' from 'Buy' in March 2026, alongside existing 'Underweight', 'Equal Weight', and 'Sell' ratings. This shift in sentiment reflects growing skepticism about the near-term turnaround and the achievability of forward earnings estimates.
- Premium Trailing Valuation vs. Weak Earnings: The trailing PE of 25.25x trades at a premium to the sector average, yet is based on depressed recent earnings. This creates a valuation overhang; if the expected earnings rebound falters, the stock faces significant multiple compression risk from its current elevated trailing multiple.
ZBH Technical Analysis
The stock is in a pronounced downtrend, having declined 13.47% over the past year and currently trading at just 17.1% of its 52-week range, based on a current price of $83.7 relative to a 52-week high of $108.29 and low of $79.12. This positioning near the lower bound of its annual range suggests the stock is deeply oversold, presenting a potential value opportunity but also indicating significant negative momentum and bearish sentiment that could persist. Recent momentum has been sharply negative, with the stock down 11.15% over the past month and 13.22% over the past three months, significantly underperforming the S&P 500 which gained 5.6% and 8.42% over the same periods, respectively. This severe underperformance, evidenced by a 1-month relative strength of -16.75, confirms the downtrend is accelerating and highlights substantial selling pressure. Key technical levels are clear, with immediate support at the 52-week low of $79.12 and major resistance at the 52-week high of $108.29. A breakdown below $79.12 could trigger further selling, while a sustained move above this year's downtrend would be needed to signal a reversal. The stock's beta of 0.473 indicates it is less volatile than the broader market, which, combined with its defensive healthcare sector, may not have shielded it from recent declines, suggesting company-specific or industry-wide concerns are at play.
Beta
0.47
0.47x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$79-$108
Price range past year
Annual Return
-12.2%
Cumulative gain past year
| Period | ZBH Return | S&P 500 |
|---|---|---|
| 1m | -10.2% | +4.0% |
| 3m | -12.4% | +8.2% |
| 6m | -4.8% | +11.5% |
| 1y | -12.2% | +24.3% |
| ytd | -5.4% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ZBH Fundamental Analysis
Revenue growth has shown resilience but with notable quarterly volatility; Q4 2025 revenue reached $2.24 billion, representing a 10.9% year-over-year increase, yet this followed a sequential decline from Q3's $2.00 billion. Segment data reveals the core business is driven by Knees ($911 million), Hips ($555.4 million), and S.E.T. ($587.6 million) for the latest period, indicating a balanced portfolio but exposing the company to cyclical trends in elective orthopedic procedures. The growth trajectory suggests recovery from prior periods but faces near-term headwinds as evidenced by the sequential dip. Profitability is present but margins have compressed significantly; net income for Q4 2025 was $139.5 million, yielding a net margin of 6.2%, a sharp decline from the 11.5% net margin in Q3 2025. The gross margin of 64.68% in Q4, while healthy, also fell from 72.05% in the prior quarter, indicating potential pricing pressure, mix shifts, or increased costs. This margin volatility, against a backdrop of a trailing twelve-month free cash flow of $1.85 billion, suggests the company is profitable and cash-generative but facing earnings quality challenges. The balance sheet is solid with a current ratio of 1.98 indicating strong short-term liquidity, and a moderate debt-to-equity ratio of 0.59. The company generated substantial free cash flow of $1.85 billion (TTM), providing ample internal funding for growth initiatives, dividends, and share repurchases. Return on equity of 5.55% and return on assets of 4.10% are modest, reflecting the capital-intensive nature of the business and the recent earnings pressure, but the strong cash flow generation mitigates financial risk.
Quarterly Revenue
$2.2B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.64%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ZBH Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 25.25x, while the forward PE is significantly lower at 9.31x, based on estimated EPS of $11.115. This wide gap implies the market expects a significant earnings recovery in the coming year, pricing in the recent profit slump as temporary. Compared to sector averages, Zimmer Biomet's trailing PE of 25.25x trades at a premium, though the forward multiple of 9.31x would represent a discount if earnings estimates are met, indicating the current price embeds skepticism about the achievability of those forecasts. Historically, the stock's own PE ratio has fluctuated significantly, with recent quarterly data showing a range from approximately 15x to over 38x over the past few years. The current trailing PE of 25.25x sits roughly in the mid-point of this historical range, suggesting the market is not pricing in extreme optimism nor pessimism relative to the company's own history, but awaiting clarity on the earnings rebound.
PE
25.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -77x~471x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks stem primarily from severe and volatile profitability. The Q4 2025 net margin of 6.2% represents a near halving from the prior quarter, raising red flags about cost inflation, pricing power, or product mix issues. While the company generates robust annual free cash flow of $1.85 billion, this earnings volatility challenges the reliability of forward EPS estimates of $11.115. Furthermore, revenue concentration in cyclical large joint procedures (~66% of sales) exposes the top line to deferrals during economic uncertainty, though recent 10.9% YoY growth shows resilience.
Market & Competitive Risks are heightened by the stock's valuation positioning. Despite recent declines, the trailing PE of 25.25x remains at a premium to the sector, creating compression risk if earnings do not rebound sharply. The stock's low beta of 0.473 has not provided defense, as it has dramatically underperformed the rising market, indicating company-specific concerns are dominating. Competitive pressures in the orthopedic device market and potential regulatory headwinds on pricing could further pressure the already declining gross margins, which fell over 700 basis points sequentially in Q4.
Worst-Case Scenario involves a failure of the earnings recovery narrative, triggering a downward spiral. If Q4 margin compression is not reversed, forward EPS estimates are cut, invalidating the cheap forward PE thesis. Combined with the negative technical momentum and analyst downgrades, this could lead to a re-rate to a distressed valuation. The realistic downside would be a test and break of the 52-week low of $79.12, with potential for a 15-20% further decline from there, aligning with the stock's historical max drawdown of -26.12%. From the current $83.7, this scenario implies a potential loss of 15-25%, driving the stock into the low-$70s.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The severe Q4 margin compression (net margin fell to 6.2%) may be structural, jeopardizing forward EPS estimates. 2) Sentiment & Momentum Risk: The stock is in a sharp downtrend, down 11.15% in a month, and analyst sentiment is turning cautious (e.g., BTIG downgrade). This can become a self-fulfilling prophecy. 3) Valuation Compression Risk: If the earnings rebound fails, the premium trailing PE of 25.25x could compress sharply. 4) Cyclical Demand Risk: ~66% of revenue comes from elective large joint procedures, which could soften in an economic downturn.
The 12-month forecast is bifurcated, with a base case target of $95-$105 (55% probability), a bull case target of $108-$118 (25%), and a bear case target of $70-$80 (20%). The base case, which is most likely, assumes the company gradually improves margins and meets the current forward EPS estimate of $11.115, leading the stock to grind towards the analyst-implied target near $103. The key assumption is that Q4's profit weakness is temporary and manageable. The forecast hinges almost entirely on the company's ability to demonstrate sequential earnings improvement in the coming quarters.
ZBH sends mixed valuation signals. On a forward-looking basis, it appears deeply undervalued, trading at a forward PE of just 9.31x based on estimated EPS of $11.115. This is a discount to both its sector and its own historical range. However, on a trailing basis, its PE of 25.25x is at a premium, reflecting recent earnings weakness. The market is therefore pricing in a significant earnings recovery. The stock is fairly valued for the high level of uncertainty it carries; it is not cheap enough to ignore the operational risks, nor is it so expensive that the downside is large if the recovery occurs.
ZBH is a high-conviction value idea but a low-conviction near-term buy. For investors with a 2-3 year horizon who believe the company will stabilize its margins, the forward PE of 9.31x and 23.6% implied upside to analyst targets present a compelling risk/reward. However, given the severe recent margin compression, negative price momentum, and cautious analyst sentiment, it is not a good buy for short-term traders or risk-averse investors. It is a suitable buy primarily for patient value investors willing to average in on weakness, with the understanding that the thesis may take several quarters to materialize.
ZBH is unequivocally suited for a long-term investment horizon, with a suggested minimum holding period of 18-24 months. The stock's low beta of 0.473 and 1.07% dividend yield offer some defensive characteristics, but its current thesis is based on an operational turnaround that will take time to validate. The high near-term volatility and negative momentum make it a poor candidate for short-term trading. Long-term investors can look through the quarterly noise to the underlying value of the market-leading business and strong cash flows, allowing time for the margin recovery story to unfold.
